Clinical Trials Search at Vanderbilt-Ingram Cancer Center
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
Miscellaneous
Miscellaneous
The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or
the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601
monotherapy and in combination with gemcitabine.
the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601
monotherapy and in combination with gemcitabine.
Miscellaneous
I
Davis, Elizabeth
NCT05389462
VICCPHI2225